Strong Financial Performance
Revenue grew 5% to $11.12 billion. Adjusted operating income increased by 9% to $2.59 billion with a 100 basis point expansion in operating margin to 23.3%. Raised full-year guidance for revenue and earnings.
Growth in Pharma and Biotech
Pharma and biotech segments showed mid-single-digit growth, driven by bioproduction and analytical instruments.
Innovation in Clinical Next-Gen Sequencing
FDA approval for OncoMindDx Express test and launch of Oncomine Comprehensive Assay Plus, enhancing genomic profiling and precision medicine.
Significant Collaborations
Strategic collaboration with OpenAI to embed advanced technology into products and operations, enhancing productivity and drug development.
Capital Deployment
Completed acquisition of filtration and separation business, closed acquisition of Ridgefield, NJ sterile finish site, and repurchased $1 billion of shares.
Bioproduction Business Success
Bioproduction business exhibited excellent growth with bookings outpacing revenue growth.